12 / 24
‘’Real World’’ Data Analysis: Similar OS
With 1L FOLFIRINOX and
nab
-P + Gem in mPCA
FOLFRINOX
mOS = 13.8 months
nab
-P + Gem
mOS = 12.1 months
Kim SS, et al.
J Clin Oncol.
2018;36(4S): Abstract 376.
•
A retrospective study; 654 patients
•
Data were colected from medical records by oncologists
in the US to represent clinical practice
100
75
50
25
0
0 5 10 15 20 25
Patient 270 258 197 93 19
0 FFX
at Risk 308 276 218 101 12 0
nab
-P+G
Proportion Free of Event, %
Months
Overall Survival
FFX vs
nab
-P+G
Unadjusted HR 0.86 (0.65-1.13);
P
= .28
Adjusted HR 0.99 (0.74-1.34);
P
= .96
Weighted log-rank test
P
= .28
First-Line Therapy
FFX
nab
-P + Gem
1L, first-line; FFX, FOLFIRINOX
‘’ eal orld’’ ata nalysis: Si ilar S
ith 1L F LFI I
X and
nab
-P + e in P
FOLFRINOX
mOS = 13.8 months
nab
-P + Gem
mOS = 12.1 months
Kim SS, et al.
J Clin Oncol.
2018;36(4S): Abstract 376.
•
A retrospective study; 654 patients
•
Data were colected from medical records by oncologists
in the US to represent clinical practice
100
75
50
25
0
0 5 10 15 20 25
Patient 270 258 197 93 19
0 FFX
at Risk 308 276 218 101 12 0
nab
-P+G
Proportion Free of Event, %
Months
Overall Survival
FFX vs
nab
-P+G
Unadjusted HR 0.86 (0.65-1.13);
P
= .28
Adjusted HR 0.99 (0.74-1.34);
P
= .96
Weighted log-rank test
P
= .28
First-Line Therapy
FFX
nab
-P + Gem
1L, first-line; FFX, FOLFIRINOX